Conceived and designed the experiments: ABB JAGS. Performed the experiments: ABB BMM BWK AK EW SM. Analyzed the data: ABB BMM BWK AK SM JAGS. Contributed reagents/materials/analysis tools: TK SS. Wrote the manuscript: ABB JAGS.
The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in Kenya in 2011. Introduction of any PCV will perturb the existing pneumococcal population structure, thus the aim was to genotype pneumococci collected in Kilifi before PCV10.
Using multilocus sequence typing (MLST), we genotyped >1100 invasive and carriage pneumococci from children, the largest collection genotyped from a single resource-poor country and reported to date. Serotype 1 was the most common serotype causing invasive disease and was rarely detected in carriage; all serotype 1 isolates were members of clonal complex (CC) 217. There were temporal fluctuations in the major circulating sequence types (STs); and although 1-3 major serotype 1, 14 or 23F STs co-circulated annually, the two major serotype 5 STs mainly circulated independently. Major STs/CCs also included isolates of serotypes 3, 12F, 18C and 19A and each shared ≤2 MLST alleles with STs that circulate widely elsewhere. Major CCs associated with non-PCV10 serotypes were predominantly represented by carriage isolates, although serotype 19A and 12F CCs were largely invasive and a serotype 10A CC was equally represented by invasive and carriage isolates.
Understanding the pre-PCV10 population genetic structure in Kilifi will allow for the detection of changes in prevalence of the circulating genotypes and evidence for capsular switching post-vaccine implementation.
The introduction of pneumococcal conjugate vaccine (PCV) into immunisation programmes in well-resourced countries led to a significant reduction in pneumococcal morbidity and mortality [
In well-resourced countries, PCV introduction led to a significant overall reduction in the incidence of invasive pneumococcal disease due to vaccine serotypes. PCV also led to a profound reduction in the prevalence of nasopharyngeal carriage of vaccine serotypes among healthy children, but with a compensatory rise in the prevalence of nonvaccine serotypes. This resulted in fundamental changes in the transmission patterns of serotypes, which had an effect on disease: the reduction in transmission of vaccine serotype pneumococci led to a herd-protection effect, benefiting older unvaccinated individuals, and the increased circulation of nonvaccine serotypes led to ‘serotype replacement disease’, which attenuated the net benefit of PCV introduction. However, many nonvaccine serotypes appear to be inherently less invasive than vaccine serotypes, thus the reduction in invasive disease caused by vaccine serotypes has, in most populations, exceeded the increase in serotype replacement disease [
In resource-poor countries, much less is known about which serotypes and genotypes are circulating at a population level, thus the impact of PCV introduction on the pneumococcal population structure and the potential for evolution in response to vaccine selective pressure cannot easily be predicted based on the experience of introducing PCV to well-resourced countries. Therefore, in this study we used MLST to provide the first large-scale characterisation of >1100 invasive and colonising pneumococcal isolates from a single resource-poor country, with the aim of revealing the population structure prior to PCV10 introduction.
The project, SSC#1357, entitled “The effect of routine immunization with Pneumococcal Conjugate Vaccine in children on the strain structure of invasive and carriage isolates of
Invasive isolates were recovered from the blood, cerebrospinal fluid or pleural fluid of ill children <15 years of age from 1994-2008 (total n = 628). All available unique patient isolates from 1994-2002 were included and isolates were systematically selected (e.g. every other isolate in the line listing of isolates) from years 2003-2008 to obtain 25 or 50 unique patient isolates in each year’s sample for genotyping. Three isolate samples from 2003-2008 were mixed or nonviable and were not genotyped.
Carriage isolates (n = 486) were collected during two previous studies conducted in the Kilifi District. The first study was performed in 2004 and sampled the nasopharynx of healthy persons of all age groups [
In all studies, samples were cultured and pneumococci identified using standard microbiological methods. Isolates were serogrouped by latex agglutination and serotyped using the Quellung method in the Kilifi Laboratory. All invasive isolates were also serotyped by PCR using a published protocol, modified to better suit the Kilifi serotype distribution [
MLST was performed according to the S.
1114 invasive and carriage isolates were recovered from children in Kilifi from 1994-2008 and genotyped by MLST (
| All | Invasive isolates | Carriage isolates | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Serotype | isolates | 0-1y | 2-4y | 5-14y | All ages | 0-1y | 2-4y | All ages | |
| 161 | 33 | 37 | 88 | 158 | 0 | 3 | 3 | ||
| 107 | 37 | 13 | 6 | 56 | 25 | 26 | 51 | ||
| 104 | 17 | 4 | 4 | 25 | 38 | 41 | 79 | ||
| 103 | 51 | 12 | 13 | 76 | 15 | 12 | 27 | ||
| 6A | 93 | 28 | 7 | 6 | 41 | 25 | 27 | 52 | |
| 86 | 33 | 8 | 4 | 45 | 19 | 22 | 41 | ||
| 45 | 30 | 5 | 10 | 45 | 0 | 0 | 0 | ||
| 39 | 19 | 7 | 6 | 32 | 1 | 6 | 7 | ||
| 31 | 12 | 2 | 2 | 16 | 5 | 10 | 15 | ||
| 29 | 8 | 4 | 11 | 23 | 2 | 4 | 6 | ||
| 19A | 28 | 12 | 5 | 2 | 19 | 7 | 2 | 9 | |
| 35B | 26 | 6 | 0 | 0 | 6 | 9 | 11 | 20 | |
| 15B/C | 23 | 2 | 1 | 0 | 3 | 7 | 13 | 20 | |
| 3 | 20 | 8 | 1 | 6 | 15 | 3 | 2 | 5 | |
| 11A | 20 | 2 | 1 | 0 | 3 | 7 | 10 | 17 | |
| 10A | 19 | 6 | 0 | 3 | 9 | 6 | 4 | 10 | |
| 23B | 18 | 2 | 0 | 0 | 2 | 3 | 13 | 16 | |
| 12F | 16 | 5 | 2 | 7 | 14 | 1 | 1 | 2 | |
| 15A | 16 | 2 | 3 | 0 | 5 | 7 | 4 | 11 | |
| 13 | 15 | 2 | 0 | 0 | 2 | 6 | 7 | 13 | |
| 34 | 11 | 3 | 0 | 0 | 3 | 3 | 5 | 8 | |
| 16F | 9 | 2 | 0 | 1 | 3 | 3 | 3 | 6 | |
| 7C | 9 | 0 | 1 | 0 | 1 | 4 | 4 | 8 | |
| 19B | 8 | 0 | 1 | 0 | 1 | 3 | 4 | 7 | |
| 20 | 7 | 0 | 0 | 0 | 0 | 1 | 6 | 7 | |
| 21 | 6 | 1 | 0 | 0 | 1 | 1 | 4 | 5 | |
| 24F | 7 | 2 | 1 | 1 | 4 | 0 | 3 | 3 | |
| 23A | 5 | 0 | 0 | 0 | 0 | 2 | 3 | 5 | |
| 35A | 5 | 0 | 0 | 0 | 0 | 2 | 3 | 5 | |
| 29 | 4 | 2 | 0 | 1 | 3 | 1 | 0 | 1 | |
| 38 | 4 | 1 | 1 | 0 | 2 | 1 | 1 | 2 | |
| 10F | 4 | 2 | 1 | 0 | 3 | 0 | 1 | 1 | |
| 17F | 4 | 0 | 0 | 0 | 0 | 2 | 2 | 4 | |
| 10B | 3 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | |
| 33B | 3 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | |
| 3 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | ||
| 9L | 3 | 0 | 0 | 2 | 2 | 0 | 1 | 1 | |
| 8 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | |
| 37 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | |
| 18F | 2 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | |
| 28F | 2 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | |
| 33D | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | |
| 35F | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | |
| 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | |
| 18 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| 31 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| 15F | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| 18B | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | |
| 22A | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | |
| 9N | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | |
| nontypeable | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | |
| Total | 1114 | 338 | 117 | 173 | 628 | 217 | 269 | 486 | |
Serotypes in boldface font are included in PCV10. Invasive isolates were serotyped by both Quellung and PCR; discordant results were generally at the level of serotype (e.g. 6A vs. 6B). Testing was repeated until consensus was achieved and the consensus serotypes were used in this study.
There were 21 major (>15 isolate representatives) CCs identified among the entire collection of pneumococci, 13 of which were of PCV10 serotypes and 8 of which were found among non-PCV10 serotypes (
| CC | ST | Total | Invasive | Carriage | Predominant serotype | Other serotype(s) |
|---|---|---|---|---|---|---|
| 2171 | -- | 161 | 158 | 3 | 1 (100%) | - |
| 217 | 106 | 104 | 2 | 1 | - | |
| 613 | 27 | 26 | 1 | 1 | - | |
| 614 | 26 | 26 | 0 | 1 | - | |
| Other | 2 | 2 | 0 | 1 | - | |
| 2464 | -- | 24 | 20 | 4 | 4 (95.8%) | 2 |
| 853 | 20 | 17 | 3 | 4 | - | |
| Other | 4 | 3 | 1 | 4 (75.0%) | 2 | |
| 2895 | -- | 44 | 44 | 0 | 5 (100%) | - |
| 245 | 26 | 26 | 0 | 5 | - | |
| 289 | 14 | 14 | 0 | 5 | - | |
| Other | 4 | 4 | 0 | 5 | - | |
| 7069V | -- | 17 | 5 | 12 | 9V (100%) | - |
| 706 | 7 | 2 | 5 | 9V | - | |
| 5283 | 6 | 2 | 4 | 9V | - | |
| Other | 4 | 1 | 3 | 9V | - | |
| 138118C | -- | 35 | 28 | 7 | 18C (100%) | - |
| 1381 | 31 | 24 | 7 | 18C | - | |
| Other | 4 | 4 | 0 | 18C (75.0%) | 18B | |
| 8546B | -- | 30 | 13 | 17 | 6B (86.7%) | 6A |
| 854 | 28 | 13 | 15 | 6B (85.7%) | 6A | |
| Other | 2 | 0 | 2 | 6B | - | |
| 27136B | -- | 24 | 17 | 7 | 6B (91.7%) | 6A, 23F |
| 2713 | 10 | 7 | 3 | 6B | - | |
| 5302 | 6 | 6 | 0 | 6B | - | |
| Other | 8 | 4 | 4 | 6B (75.0%) | 6A, 23F | |
| 6314 | -- | 61 | 42 | 19 | 14 (100%) | - |
| 842 | 44 | 27 | 17 | 14 | - | |
| 2716 | 5 | 5 | 0 | 14 | - | |
| Other | 12 | 10 | 2 | 14 | - | |
| 23014,3 | -- | 40 | 31 | 9 | 14 (67.5%) | 3 |
| 230 | 24 | 20 | 4 | 14 | - | |
| 700 | 11 | 8 | 3 | 3 | - | |
| Other | 5 | 3 | 2 | 14 (60.0%) | 3 | |
| 84419F | -- | 50 | 10 | 40 | 19F (92.0%) | 11A, 14, 23A, 23F |
| 844 | 19 | 6 | 13 | 19F (94.7%) | 14 | |
| 5339 | 15 | 2 | 13 | 19F (80.0%) | 11A, 23A, 23F | |
| 5367 | 5 | -- | 5 | 19F | - | |
| Other | 11 | 2 | 9 | 19F | - | |
| 271519F | -- | 21 | 9 | 12 | 19F (95.2%) | 14 |
| 2715 | 11 | 4 | 7 | 19F | - | |
| 6088 | 6 | 4 | 2 | 19F (83.3%) | 14 | |
| Other | 4 | 1 | 3 | 19F | - | |
| 271423F | -- | 43 | 23 | 20 | 23F (100%) | - |
| 2714 | 39 | 22 | 17 | 23F | - | |
| Other | 4 | 1 | 3 | 23F | - | |
| 98823F | -- | 25 | 16 | 9 | 23F (88.0%) | 4, 14, 19F, 35B |
| 988 | 17 | 10 | 7 | 23F (94.1%) | 19F | |
| Other | 8 | 6 | 2 | 23F (62.5%) | 4, 14, 35B |
Note: CC = clonal complex; ST = sequence type; ‘-’ indicates that no other serotypes were detected.
CCs with >15 isolate representatives shown here; STs within a CC that have fewer than 5 isolate representatives are grouped as “Other”.
| CC | ST | Total | Invasive | Carriage | Predominant serotype(s) | Other serotypes |
|---|---|---|---|---|---|---|
| 70113,15BC | -- | 31 | 5 | 26 | 13 (48.4%), 15BC (16.1%) | 6B, 9V, 23F |
| 701 | 18 | 5 | 13 | 13 (61.1%), 6B (16.7%) | 9V (11.1%), 15BC (11.1%) | |
| 5340 | 6 | -- | 6 | 15BC | - | |
| Other | 7 | 0 | 7 | 13 (57.1%), 15BC (28.6%) | 23F | |
| 590215A | -- | 27 | 8 | 19 | 15A (68.8%) | 9V, 11A, 15BC, 18C |
| 840 | 8 | 3 | 5 | 9V (37.5%) | 35A (25.0%), 11A, 15BC, 35B | |
| 5336 | 7 | 3 | 4 | 15A (71.4%) | 15BC, 18C | |
| Other | 12 | 2 | 10 | 15A (50.0%), 35A (25.0%) | 11A (16.7%), 9V | |
| 84719A | -- | 26 | 18 | 8 | 19A (100%) | - |
| 847 | 20 | 13 | 7 | 19A | - | |
| Other | 6 | 5 | 1 | 19A | - | |
| 4996A | -- | 25 | 7 | 18 | 6A (88.0%) | 6A/B, 15BC |
| 499 | 21 | 6 | 15 | 6A (95.2%) | 15BC | |
| Other | 4 | 1 | 3 | 6A (75.0%), 6B (25.0%) | - | |
| 114635B | -- | 25 | 5 | 20 | 35B (84.0%) | 17F, 23F, 29 |
| 1146 | 16 | 4 | 12 | 35B (87.5%) | 23F, 29 | |
| Other | 9 | 1 | 8 | 35B (77.8%) | 17F | |
| 85210A | -- | 19 | 9 | 10 | 10A (89.5%) | 10B |
| 852 | 18 | 8 | 10 | 10A (88.9%) | 10B | |
| 5304 | 1 | 1 | 0 | 10A | - | |
| 9146A | -- | 18 | 3 | 15 | 6A (88.9%) | 6B |
| 5354 | 13 | 2 | 11 | 6A (84.6%) | 6B | |
| Other | 5 | 1 | 4 | 6A | - | |
| 98912F | -- | 16 | 14 | 2 | 12F (100%) | - |
| 989 | 9 | 9 | 0 | 12F | - | |
| 5352 | 6 | 4 | 2 | 12F | - | |
| 5797 | 1 | 1 | 0 | 12F | - |
Note: CC = clonal complex; ST = sequence type; ‘-’ indicates that no other serotypes were detected.
CCs with >15 isolate representatives shown here; STs within a CC that have fewer than 5 isolate representatives are grouped as “Other”.
161 serotype 1 isolates from Kilifi were genotyped and all were members of CC2171 (note: STserotype;
Vaccine serotype 4 isolates from Kilifi were predominantly invasive isolates of ST853, which are members of the widely distributed CC2464 (
All of the vaccine serotype 5 isolates (n = 44) were from cases of invasive disease, and all were members of CC2895. ST289 is the widely-distributed Pneumococcal Molecular Epidemiology Network (PMEN) clone represented by the Columbia5-19 strain [
One major serotype 9V CC was identified (CC7069V) and 100% of the CC706 isolates expressed serotype 9V. 39 vaccine serotype 18C isolates were characterised in this study and 35 of these were members of CC138118C. ST138118C shares only the
Among vaccine serotypes 6B, 14, 19F and 23F there were two major CCs circulating for each serotype and in each case the two CCs defined a large proportion of the isolate representatives for each serotype: 45% of 107 serotype 6B isolates; 85% of 103 serotype 14 isolates; 64% of 104 serotype 19F isolates; and 76% of 86 serotype 23F isolates (
CCs 70113,15BC, 4996A, 114635B, 85210A, 9146A and 590215A were major clones found in Kilifi, predominantly comprised of isolates from carriage rather than invasive disease (
All serotype 12F isolates (n = 16) from Kilifi were members of CC98912F and isolates of this CC have also been found elsewhere in Africa [
Since the invasive isolate dataset in Kilifi spanned 15 years, we were able to explore temporal variation among circulating STs and CCs over that extended period of time. 12 CCs were comprised of >10 invasive isolate representatives in total over the time period, which represented 68% (424/628) of the entire invasive collection (
The total number of isolates genotyped each year from 1994-2008 is stated in parentheses in the y-axis labels.
Invasive isolates were collected from 1994-2008 and the major STs associated with serotypes 1 (
Invasive isolates were collected from 1994-2008 and the major STs associated with serotypes 14 (
Major STs associated with serotypes 12F, 19A, 6B, 4 and 18C are depicted for each surveillance year from 1994-2008. The total number of isolates genotyped each year (see Methods) is stated in parentheses in the x-axis labels.
The introduction of PCV10 is vitally important for Kenya since the morbidity and mortality associated with pneumococcal disease is high. The incidence of invasive disease associated with PCV10 serotypes has decreased since vaccination began [
Post-vaccine changes in the US were revealed because the pre-vaccine pneumococcal population genetic structure in the US was well defined. Active, population- and laboratory-based invasive disease surveillance has been on-going in the US since 1995 (5 years before PCV was introduced) and two studies specifically characterised large, representative collections of pneumococci to identify the pre-PCV7 baseline set of genotypes circulating in the US [
MLST has been used to characterise many thousands of pneumococci collected across Europe, North and South America, Australia and Asia and many of the major STs within countries have disseminated across continents, e.g. STs 8123F,19F, 906B, 1569V, 914, 12414, 11318C, 21812F, 1917F, 1803, 19919A [
An interesting observation was the temporal fluctuation in STs that expressed the same serotypes, accepting that for some of these serotypes the numbers observed each year were small. There were no major changes in Kilifi District (e.g. changes in laboratory methods or practice, antimicrobial use or stewardship, early vaccine uptake, etc.) over the surveillance period that would have contributed to big fluctuations in the circulating serotypes or genotypes. The prevalence of circulating serotypes is known to vary and thus temporal fluctuations in circulating serotypes and genotypes in Kilifi were not surprising [
Several major CCs were comprised of nonvaccine serotype isolates (10A, 13, 15A, 15BC and 35B) primarily recovered from healthy children, although they were also recovered from children with invasive disease so the potential for serotype replacement disease remains. Serotypes 10A, 15BC and 35B increased in prevalence in the US post-PCV7 vaccine [
In this study we established the baseline set of genotypes in Kilifi prior to PCV10 introduction, which will allow for the detection of changes in prevalence of pre-existing STs and the identification of new nonvaccine STs (as putative imports or new recombinants). It will be essential that any perceived increases or decreases in serotype or genotype prevalence after PCV10 vaccination is established in Kilifi be considered in the context of the pre-vaccine genotypic landscape.
(DOCX)
Click here for additional data file.
(DOCX)
Click here for additional data file.
The authors acknowledge the use of the pneumococcal MLST database, which is located at Imperial College London and is funded by the Wellcome Trust; in particular, we thank Cynthia Bishop for her effort in entering the many new alleles and sequence types that were identified in this study. This paper is published with the permission of the Director of the Kenya Medical Research Institute. ABB and JAGS are both Wellcome Trust Research Fellows. Co-author Eva Wanjiru tragically passed away in 2012 shortly after delivering her baby. She was an important part of the phenotyping team in this study and with the permission of her husband is included in this paper as a posthumous author.